Retrophin’s RE-024 Gains EU Orphan Drug Status

Retrophin has won EU orphan drug status for RE-024, a phosphopantothenate replacement therapy for pantothenate kinase-associated neurodegeneration.

The FDA also awarded the candidate orphan drug designation for the same indication, as well as fast track status.